An open-label study of the effect of the addition of MabThera to standard chemotherapy on clinical response in patients with previously untreated mantle cell lymphoma.

Trial Profile

An open-label study of the effect of the addition of MabThera to standard chemotherapy on clinical response in patients with previously untreated mantle cell lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 29 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Planned End Date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 27 Aug 2012 Planned end date changed from 1 Jul 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top